Trial Profile
A prospective study evaluating short-term effects of natalizumab and end of dose interval symptoms in patients with relapsing remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis